Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASciminib for SEcond attempt Treatment-free remission in patients with CML-CP (ASSET-CML)
jRCTs071230047Recruiting
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: TFR rate at 12 months after discontinuation of asciminib treatment. Started Aug 2023; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on jRCTs071230047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230047.